Sydney, Australia 20 July 2021 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that its 64Cu SAR-bisPSMA clinical trial in patients with confirmed prostate cancer is open for recruitment at two sites, GenesisCare CTA Medical Clinic, Perth and Nepean Hospital, Sydney.
Clarity’s Executive Chairman, Dr Alan Taylor, commented, “We are very excited to open this trial for patients with newly diagnosed prostate cancer using our optimised PSMA agent, 64Cu SAR-bisPSMA, that has the novel combination of two targeting agents attached to our SAR Technology. The preclinical data to date is compelling, with both higher tumour uptake and greater tumour retention compared to the single targeted products utilised by other radiopharmaceutical products on the market, and we look forward to recruiting our first patient for this trial shortly.”
The PROPELLER trial is a Phase I Positron Emission Tomography (PET) imaging trial of participants with confirmed prostate cancer using 64Cu SAR-bisPSMA. It is a 30-patient clinical trial conducted across three sites in Australia (NCT04839367)1. PROPELLER is a multi-centre, blinded review, dose ranging, non-randomised study of 64Cu-SAR-bisPSMA administered to patients with confirmed prostate cancer prior to radical prostatectomy. The primary endpoints of the trial are safety, tolerability and efficacy in the detection of primary prostate cancer compared to histopathology.
Dr Taylor said: “Prostate cancer is one of the largest indications in oncology, and due to the logistical, manufacturing and imaging issues related to other radiopharmaceuticals, represents a lucrative opportunity for us to enter this space with our Targeted Copper Theranostics (TCT) platform. Clarity’s centralised manufacture and broad distribution model coupled with the flexibility of imaging at later time points, gives us confidence to believe that we can provide a large patient population with early, accurate and precise detection of prostate cancer and improve patient outcomes. We look forward to further progressing the development of our SAR-bisPSMA product and exploring the benefits of our TCT platform for patients with prostate cancer, including in our upcoming US based 64Cu/67Cu bis-PSMA theranostic trial (SECuRE trial (NCT04868604)2 which is due to commence shortly. The progress of these two trials will get us one step closer to our ultimate goal of developing better treatments for children and adults with cancer.”
References
- ClinicalTrials.gov Identifier: NCT04839367 <https://clinicaltrials.gov/ct2/show/NCT04839367>
- ClinicalTrials.gov Identifier: NCT04868604 <https://clinicaltrials.gov/ct2/show/NCT04868604>
About Clarity
Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children. For more information visit:
www.claritypharmaceuticals.com
Media Contact
Dr Alan Taylor
Executive Chairman
+61 (0)413 871 165
ataylor@claritypharm.com
